Skip to main content

Advertisement

Table 5 Prognostic factors for distant disease-free survival: multivariate analysis

From: Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study

  Model 1 (N = 570)   Model 2 (N = 575)  
  HR (95 % CI) p-valuea HR (95 % CI) p-valuea
Age
  < 35 1   1  
  ≥ 35 0.4 [0.1–2.1] 0.344 0.4 [0.09–1.8] 0.251
SBR Grade
 1–2 1   NA  
 3 3.4 [1.5–7.6] 0.0027 NA  
Pathological tumor size
 pT1 1   1  
 pT2 1.0 [0.5–2.0] 0.932 1.0 [0.5–2.1] 0.847
 pT3-T4 0.7 [0.09–5.3] 0.733 0.7 [0.09–5.5] 0.763
PVI
 No 1   1  
 Yes 1.7 [0.8–3.6] 0.155 1.5 [0.7–3.2] 0.275
Hormone receptors
 Negative 1   NA  
 Positive 0.9 [0.4–2.0] 0.865 NA  
HER2
 Positive 1   NA  
 Negative 0.7 [0.2–2.0] 0.605 NA  
IHC subtypes
 Luminal A NA   1  
 Luminal B-HER2–negative NA   4.4 [1.7–11.5] 0.0018
 Luminal B-HER2-positive NA   1.2 [0.2–5.9] 0.775
 HER2 NA   2.8 [0.7–10.9] 0.118
 Triple-negative NA   3.4 [1.3–8.7] 0.0074
  1. HR hazard ratio, PVI peritumor vascular invasion
  2. aWald test